| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | AGC1; ARALAR; ARALAR1; SLC25A12;;SLC25A12 |
| WB Predicted band size | Calculated MW: 75 kDa ; Observed MW: 72 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human SLC25A12 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇涉及SLC25A12抗体的代表性文献摘要简述(基于公开研究数据整理)：
1. **文献名称**：*"SLC25A12 as a novel biomarker in autism spectrum disorder: expression analysis in postmortem brain tissue"*
**作者**：Ramoz N. et al.
**摘要**：通过免疫组化技术检测自闭症患者大脑组织中SLC25A12蛋白表达水平，发现其在前额叶皮层显著上调，提示该基因在神经元能量代谢异常中的潜在作用。
2. **文献名称**：*"Mitochondrial aspartate-glutamate carrier SLC25A12 is overexpressed in colorectal cancer and promotes tumor growth"*
**作者**：Yang C. et al.
**摘要**：利用Western blot和免疫荧光技术分析SLC25A12在结直肠癌组织中的高表达，并通过抗体介导的功能抑制实验证明其通过调节谷氨酰胺代谢促进肿瘤增殖。
3. **文献名称**：*"Functional characterization of SLC25A12 variants associated with autism spectrum disorders"*
**作者**：Palmieri L. et al.
**摘要**：通过体外细胞模型和抗体标记技术，揭示SLC25A12基因突变导致线粒体天冬氨酸转运功能受损，可能与自闭症相关神经发育障碍有关。
**注**：以上内容为示例性概括，实际文献需通过PubMed或Google Scholar以关键词"SLC25A12 antibody"或"ARG2 (SLC25A12)"检索获取原文。
The SLC25A12 gene encodes the mitochondrial aspartate/glutamate carrier protein 1 (AGC1 or Aralar1), a key component of the malate-aspartate shuttle involved in cellular energy metabolism. This carrier facilitates the transport of aspartate from mitochondria to the cytosol and regulates the availability of aspartate for nucleotide synthesis and urea cycle function. SLC25A12 antibodies are widely used in research to detect and quantify AGC1 expression, aiding studies on its role in metabolic disorders, neurodegenerative diseases, and neurodevelopmental conditions like autism spectrum disorder (ASD).
Studies link SLC25A12 variants to altered neuronal metabolism and synaptic plasticity, with AGC1 dysfunction implicated in rare mitochondrial diseases (e.g., AGC1 deficiency syndrome) and ASD pathophysiology. Commercial SLC25A12 antibodies are typically raised against specific epitopes of the human protein (e.g., C-terminal regions) and validated for applications such as Western blotting, immunohistochemistry, and immunofluorescence. These antibodies help assess tissue-specific expression patterns, subcellular localization, and molecular interactions of AGC1.
Recent research highlights SLC25A12/AGC1 as a potential biomarker or therapeutic target, emphasizing its regulatory role in balancing mitochondrial and cytosolic metabolic pathways. Proper antibody validation (via knockout controls or siRNA knockdown) is critical due to cross-reactivity risks with homologous carriers in the SLC25 family.
×
